pdf string | doi string | doi_sourse string | supplementary int64 | title string | publisher string | year int64 | access int64 | compound_id string | compound_name string | SMILES string | SMILES_type string | metal string | target string | page_smiles int64 | origin_smiles string | page_metal int64 | origin_metal string | page_target_value float64 | origin_target_value string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C30 | null | O=C(O)CNCCNCC(=O)O.O=C([O-])CNC([O-])(O)CO.[N-2]Nc1ccc(C(=O)NC2C(O)OC(CO)C(O)C2O)cn1 | environment | Tc | null | 19 | scheme 17 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C32a | BOD | CC1=CC(C)=[N+]2C1=C(c1ccc(C(N)=N[O-])cc1)c1c(C)cc(C)n1[B-]2(F)F.CC1=CC(C)=[N+]2C1=C(c1ccc(C(N)=N[O-])cc1)c1c(C)cc(C)n1[B-]2(F)F.[O-2] | environment | Tc | null | 21 | scheme 19 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C32b | MBOD | CNC(=N[O-])c1ccc(C2C3=C(C)C=C(C)C3[B-](F)(F)C3=C(C)C=C(C)C32)cc1.CNC(=N[O-])c1ccc(C2C3=C(C)C=C(C)C3[B-](F)(F)C3=C(C)C=C(C)C32)cc1.[O-2] | environment | Tc | null | 21 | scheme 19 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C33 | null | O=C([O-])CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[O-2].[O-2].[O-2] | environment | Tc | null | 21 | scheme 19 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C35 | null | C=C(NCCCC(NCCCCc1ccc(N(CCCl)CCCl)cc1)C(=O)NC1CSSCC(C(N)=O)C(=O)C(CCNC(=N)N)NC(=O)CNC(=O)C(CC(N)=O)NC1=O)c1ccc(N=N)nc1.O=C(O)CNCCNCC(=O)O.O=C([O-])CNCCNCC(=O)O | environment | Tc | null | 22 | scheme 21 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C36 | null | CC1(C)OC(C)(C)C(C=NCCN=CC2=C([O-])C(C)(C)OC2(C)C)=C1[O-].[Cl-] | environment | Tc | null | 22 | scheme 21 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C37 | NOET | CCON(CC)C(=S)[S-].CCON(CC)C(=S)[S-].[N-3] | environment | Tc | null | 23 | scheme 22 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C38 | PHEDTC | O=C(O[Na])C(Cc1ccccc1)NC(=S)[S-].O=C(O[Na])C(Cc1ccccc1)NC(=S)[S-].[N-3] | environment | Tc | null | 23 | scheme 22 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C39 | null | CC12CCC3c4ccc(O)cc4CCC3C1CCC2(O)c1cn(CC(NC(=S)[S-])C(=O)O)nn1.CC12CCC3c4ccc(O)cc4CCC3C1CCC2(O)c1cn(CC(NC(=S)[S-])C(=O)O)nn1.[N-3] | environment | Tc | null | 23 | scheme 23 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C40 | null | [Cl-].[Cl-].[Cl-].[N-2]c1ccc(F)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1 | environment | Tc | null | 24 | scheme 24 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C41 | null | Nc1ccccc1P(c1ccccc1)c1ccccc1.Nc1ccccc1P(c1ccccc1)c1ccccc1.[Cl-].[N-]=O | environment | Tc | null | 24 | scheme 24 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C42 | null | F[P-](F)(F)(F)(F)F.Nc1ccccc1P(c1ccccc1)c1ccccc1.Nc1ccccc1P(c1ccccc1)c1ccccc1.[Cl-].[N-]=O | environment | Tc | null | 24 | scheme 24 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C43 | PHEDTC | O=C(O[Na])C(Cc1ccccc1)NC(=S)[S-].O=C(O[Na])C(Cc1ccccc1)NC(=S)[S-].[O-2] | environment | Tc | null | 26 | scheme 25 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C44 | DGDTC | OCC1OC(O)C(NC(=S)[S-])C(O)C1O.OCC1OC(O)C(NC(=S)[S-])C(O)C1O.[O-2] | environment | Tc | null | 26 | scheme 25 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C45 | MNXT | Cc1ncc([N+](=O)[O-])n1CCOC(=S)[S-].Cc1ncc([N+](=O)[O-])n1CCOC(=S)[S-].[O-2] | environment | Tc | null | 26 | scheme 25 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C46 | null | O=P(O[Na])(O[Na])C(O)(CCCNC(=S)[S-])P(=O)(O[Na])O[Na].O=P(O[Na])(O[Na])C(O)(CCCNC(=S)[S-])P(=O)(O[Na])O[Na].[N-3] | environment | Tc | null | 27 | scheme 26 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C47a | null | C[N-]Cc1cn(CCn2c([N+](=O)[O-])cnc2C)nn1.[C-]#[O+].[C-]#[O+].[C-]#[O+].[O] | environment | Tc | null | 27 | scheme 27 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C47b | null | Cc1ncc([N+](=O)[O-])n1CCn1cc(CNC(=O)[O-])nn1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 27 | scheme 27 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C48 | null | COC(=O)Cn1cc(CNc2ccccc2[O-])nn1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 27 | scheme 27 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C50a | null | N=C(N)NCc1cccc(CN(CC(=O)[O-])CC(=O)[O-])c1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 29 | scheme 28 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C50b | null | N=C(N)NCc1cccc(CN(CCN)CC(=O)[O-])c1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 29 | scheme 28 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C51 | null | NC(Cc1cn(C2OC(CO)C(O)C(O)C2O)nn1)C(=O)[O-].[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 30 | scheme 29 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C52 | null | N=C(N)NCCCC1NC(=O)CNC(=O)C(CC(N)=O)NC(=O)C(N)CSSCC(C(=O)NC(CCCCn2cc(CC(N)C(=O)[O-])nn2)C(=O)NCC(N)=O)NC1=O.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 30 | scheme 29 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C53a | null | O=C([O-])CN(CC(=O)[O-])CP(=O)([O-])[O-].[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 30 | scheme 29 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C53b | null | O=C([O-])CN(CC(=O)[O-])CP(=O)([O-])[O-].[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 30 | scheme 29 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C54 | null | O=C([O-])C1([O-])CCN(CCC#Cc2cncc(OCC3CCN3)c2)CC1=O.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 31 | scheme 30 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C55a | null | NC(CC(=O)[O-])c1cn(CCCCCCCC(=O)O)nn1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 31 | scheme 30 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C55b | null | NC(CC(=O)[O-])c1cn(CCCCCCCCCCC(=O)O)nn1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 31 | scheme 30 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C55с | null | NC(CC(=O)[O-])c1cn(CCCCCCCCCCCCCCC(=O)O)nn1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 31 | scheme 30 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | С56 | null | O=C([O-])c1ccccn1.[C-]#[O+].[C-]#[O+].[C-]#[O+].c1ccncc1 | environment | Tc | null | 32 | scheme 31 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | С57 | null | CC12CCC3c4ccc(O)cc4CCC3C1CCC2(O)c1cn(CC([NH-])C(=O)[O-])nn1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 32 | scheme 31 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | С58a | null | CN(C)c1ccc2nc(-c3ccc(OCCCCN(CC(=O)[O-])CC(=O)[O-])cc3)cnc2c1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 32 | scheme 31 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | С58b | null | CN(C)c1ccc2nc(-c3ccc(OCCCN(CC(=O)[O-])CC(=O)[O-])cc3)cnc2c1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 32 | scheme 31 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | С58c | null | CN(C)c1ccc2ncc(-c3ccc(OCCCCN(CC(=O)[O-])CC(=O)[O-])cc3)nc2c1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 32 | scheme 31 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | С58d | null | CN(C)c1ccc2ncc(-c3ccc(OCCCN(CC(=O)[O-])CC(=O)[O-])cc3)nc2c1.[C-]#[O+].[C-]#[O+].[C-]#[O+] | environment | Tc | null | 32 | scheme 31 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C59 | null | [C-]#[N+]Cc1ccccc1.[C-]#[O+].[C-]#[O+].[C-]#[O+].[S-]c1ccccn1 | environment | Tc | null | 33 | scheme 32 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C60a | null | CNC(=S)NN=Cc1ccc([N+](=O)[O-])o1.[C-]#[O+].[C-]#[O+].[C-]#[O+].[O] | environment | Tc | null | 33 | scheme 32 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C60b | null | CCNC(=S)NN=Cc1ccc([N+](=O)[O-])o1.[C-]#[O+].[C-]#[O+].[C-]#[O+].[O] | environment | Tc | null | 33 | scheme 32 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C60c | null | O=[N+]([O-])c1ccc(C=NNC(=S)Nc2ccccc2)o1.[C-]#[O+].[C-]#[O+].[C-]#[O+].[O] | environment | Tc | null | 33 | scheme 32 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C61 | null | [N-3].[c-]1ccccc1.[c-]1ccccc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1.c1ccc(P(c2ccccc2)c2ccccc2)cc1 | environment | Tc | null | 33 | scheme 33 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C62 | null | CC1(C)OC(C)(C)C(C=NCCN=CC2=C([O-])C(C)(C)OC2(C)C)=C1[O-].COCCCP(CCCOC)CCCOC.COCCCP(CCCOC)CCCOC | environment | Tc | null | 34 | scheme 34 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C63 | null | O=C([O-])C(F)(F)F.[N-]=O.c1ccc(P(CCP(c2ccccc2)c2ccccc2)c2ccccc2)cc1.c1ccc(P(CCP(c2ccccc2)c2ccccc2)c2ccccc2)cc1 | environment | Tc | null | 34 | scheme 34 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C64 | (t/T)HYNIC-DG | O=C([O-])CNC([O-])(O)CO.O=S(=O)(O[Na])c1ccc(P(c2cccc(S(=O)(=O)O[Na])c2)c2cccc(S(=O)(=O)O[Na])c2)cc1.[N-2]Nc1ccc(C(=O)NC2C(O)OC(CO)C(O)C2O)cn1 | environment | Tc | null | 35 | scheme 35 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C67 | null | COCCCN(CCP(CCOC)CCOC)CCP(CCOC)CCOC.N=C(N)NCCC1NC(=O)NC(=O)C(CCCNC(=O)C2CCN(C(=S)[S-])CC2)NC(=O)C(Cc2ccccc2)NC(=O)C(CC(=O)O)NC(=O)CNC1=O.[N-3] | environment | Tc | null | 36 | scheme 36 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C69 | null | CCC(C)C(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(=O)O)NC(=O)C[N-]C(=O)C[N-]C(=O)C[N-]C(NC([S-])N(CC)CC)c1ccccc1)C(C)C)C(=O)NC(Cc1c[nH]cn1)C(=O)N1CCCC1C(=O)NC(Cc1ccccc1)C(=O)O | environment | Tc | null | 38 | scheme 38 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C70-111 | null | CN(C)c1ccc(-c2cnc3cc(OCCCN(CC[S-])CC[N-]CC[S-])ccc3n2)cc1.[O-2] | environment | Tc | null | 38 | scheme 39 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C70-112 | null | CNc1ccc(-c2cnc3cc(OCCCN(CC[S-])CC[N-]CC[S-])ccc3n2)cc1.[O-2] | environment | Tc | null | 38 | scheme 39 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C70-113 | null | Nc1ccc(-c2cnc3cc(OCCCN(CC[S-])CC[N-]CC[S-])ccc3n2)cc1.[O-2] | environment | Tc | null | 38 | scheme 39 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C72-R1 | null | CCOCCN(CCP(CCOCC)CCOCC)CCP(CCOCC)CCOCC.O=C(Cn1cnc([N+](=O)[O-])n1)NC(C[S-])C(=O)[O-].[N-3] | environment | Tc | null | 39 | scheme 41 | 1 | title | null | null |
shahzad2021 | 10.1515/revic-2020-0021 | 10.1515/revic-2020-0021 | 0 | Recent advances in the synthesis of (<sup>99m</sup>Technetium) based radio-pharmaceuticals | Walter de Gruyter GmbH | 2,021 | 0 | C72-R2 | null | CCOCCCP(CCCOCC)CCN(CCOCC)CCP(CCCOCC)CCCOCC.O=C(Cn1cnc([N+](=O)[O-])n1)NC(C[S-])C(=O)[O-].[N-3] | environment | Tc | null | 39 | scheme 41 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | null | O.O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1 | environment | Lu | null | 7 | figure 3 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | NTA | O=C(O)CN(CC(=O)O)CC(=O)O | ligand | Lu | 12,5 | 8 | figure 4 | 1 | title | 8 | table 4 |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | EDTA | O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O | ligand | Lu | 19,8 | 8 | figure 4 | 1 | title | 8 | table 4 |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DTPA | O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O | ligand | Lu | 22,4 | 8 | figure 4 | 1 | title | 8 | table 4 |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DOTA | O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1 | ligand | Lu | 25,4 | 8 | figure 4 | 1 | title | 8 | table 4 |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DO3A | O=C(O)CN1CCNCCN(CC(=O)O)CCN(CC(=O)O)CC1 | ligand | Lu | 23 | 8 | figure 4 | 1 | title | 8 | table 4 |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | NOTA | O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CC1 | ligand | Lu | 15,3 | 8 | figure 4 | 1 | title | 8 | table 4 |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | pSCN-Bn-DOTA | O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)C(Cc2ccc(N=C=S)cc2)CN(CC(=O)O)CC1 | ligand | Lu | null | 15 | figure 12 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DOTA-NHS-ester | O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)ON2C(=O)CCC2=O)CCN(CC(=O)O)CC1 | ligand | Lu | null | 15 | figure 12 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DOTAGA | O=C(O)CN1CCN(CC(=O)O)CCN(C2CCC(=O)OC2=O)CCN(CC(=O)O)CC1 | ligand | Lu | null | 15 | figure 12 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | pSCN-Bn-DTPA | O=C(O)CN(CCN(CC(=O)O)CC(Cc1ccc(N=C=S)cc1)N(CC(=O)O)CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 12 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | 1B4M-DTPA | CC(C(Cc1ccc(N=C=S)cc1)N(CC(=O)O)CC(=O)O)N(CCN(CC(=O)O)CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 12 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | null | O=C(O)CN(CCN(CC(=O)O)CC(Cc1ccc([N+](=O)[O-])cc1)N(CC(=O)O)CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 13 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | null | CC(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(Cc1ccc([N+](=O)[O-])cc1)N(CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 13 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | null | CC(CN(CC(=O)O)CC(Cc1ccc([N+](=O)[O-])cc1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 13 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | null | O=C(O)CN(CCN(CC(=O)O)C(Cc1ccc([N+](=O)[O-])cc1)CN(CC(=O)O)CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 13 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | CHX-B | O=C(O)CN(CC(=O)O)C(Cc1ccc([N+](=O)[O-])cc1)CN(CC(=O)O)C1CCCCC1N(CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 13 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | CHX-A | O=C(O)CN(CC(=O)O)C(Cc1ccc([N+](=O)[O-])cc1)CN(CC(=O)O)C1CCCCC1N(CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 13 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | CHX-DTPA | O=C(O)CN(CCN(CC(=O)O)C1CCCCC1N(CC(=O)O)CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 13 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DTPA | O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O | ligand | Lu | null | 15 | figure 13 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | BFCA | O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)NCC(=O)NCC(=O)NCC(=O)NC(Cc2ccc(N=C=S)cc2)C(=O)O)CCN(CC(=O)O)CC1 | ligand | Lu | null | 16 | figure 14 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | MeO-DOTA | COc1ccc(N=C=S)cc1CC(C(=O)O)N1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1 | ligand | Lu | null | 16 | figure 15 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | NHS-DOTA | O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)ON2C(=O)CCC2=O)CCN(CC(=O)O)CC1 | ligand | Lu | null | 16 | figure 15 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | 1B4M | CC(CN(CC(=O)O)CC(Cc1ccc(N=C=S)cc1)N(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O | ligand | Lu | null | 16 | figure 15 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DOTA-8-Aoc-BBN[7−14]NH2 | CSCCC(NC(=O)C(CC(C)C)NC(=O)C(Cc1cnc[nH]1)NC(=O)CNC(=O)C(NC(=O)C(C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)CCCCCCCNC(=O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1)C(C)C)C(N)=O | ligand | Lu | null | 20 | figure 17 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | AMBA | C=C(CNC(=O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1)Cc1ccc(C(=O)NC(CCC(N)=O)C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)NC(C)C(=O)NC(C(=O)NCC(=O)NC(Cc2cnc[nH]2)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(N)=O)C(C)C)cc1 | environment | Lu | null | 20 | figure 18 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | RGD-dimer | N=C(N)NCCCC1NC(=O)C(CCCCNC(=O)CCC(NC(=O)N2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)C(=O)NCCCCC2NC(=O)C(Cc3ccccc3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CCCNC(=N)N)NC2=O)NC(=O)C(Cc2ccccc2)NC(=O)C(CC(=O)O)NC(=O)CNC1=O | ligand | Lu | null | 22 | figure 21 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | RGD2 | N=C(N)NCCCC1NC(=O)C(CCCCNC(=O)CCC(N)C(=O)NCCCCC2NC(=O)C(Cc3ccccc3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CCCNC(=N)N)NC2=O)NC(=O)C(Cc2ccccc2)NC(=O)C(CC(=O)O)NC(=O)CNC1=O | ligand | Lu | null | 22 | figure 21 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DOTA-RGD2 | N=C(N)NCCCC1NC(=O)C(CCCCNC(=O)CCC(NC(=O)N2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)C(=O)NCCCCC2NC(=O)C(Cc3ccccc3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CCCNC(=N)N)NC2=O)NC(=O)C(Cc2ccccc2)NC(=O)C(CC(=O)O)NC(=O)CNC1=O | environment | Lu | null | 22 | figure 21 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DOTA-Bz-RGD2 | N=C(N)NCCCC1NC(=O)C(CCCCNC(=O)CCC(NC(=S)Nc2ccc(C3CN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN3C(=O)[O-])cc2)C(=O)NCCCCC2NC(=O)C(Cc3ccccc3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CCCNC(=N)N)NC2=O)NC(=O)C(Cc2ccccc2)NC(=O)C(CC(=O)O)NC(=O)CNC1=O | environment | Lu | null | 22 | figure 21 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DTPA-Bz-RGD2 | N=C(N)NCCCC1NC(=O)C(CCCCNC(=O)CCC(NC(=S)Nc2ccc(C3CN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN3CC(=O)[O-])cc2)C(=O)NCCCCC2NC(=O)C(Cc3ccccc3)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CCCNC(=N)N)NC2=O)NC(=O)C(Cc2ccccc2)NC(=O)C(CC(=O)O)NC(=O)CNC1=O | environment | Lu | null | 22 | figure 21 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | TA-138 | Cc1cc(OCCCC(=O)NCCNC(=O)C(NC(=O)C(NC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)S(=O)(=O)O)S(=O)(=O)O)cc(C)c1S(=O)(=O)NC(CNC(=O)c1c[nH]c2ccc(CNc3ncc[nH]3)cc2c1=O)C(=O)O | ligand | Lu | null | 23 | figure 22 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | null | Nc1nc2ncc(CNc3ccc(C(=O)NC(CCC(=O)NCCCCn4cc(CNC(=O)CN5CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC5)nn4)C(=O)O)cc3)nc2c(=O)[nH]1 | ligand | Lu | null | 23 | figure 25 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | EDTMP | O=P(O)(O)CN(CCN(CP(=O)(O)O)CP(=O)(O)O)CP(=O)(O)O | ligand | Lu | null | 25 | figure 26 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | PDTMP | O=P(O)(O)CN(CCCN(CP(=O)(O)O)CP(=O)(O)O)CP(=O)(O)O | ligand | Lu | null | 25 | figure 26 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | BDTMP | O=P(O)(O)CN(CCCCN(CP(=O)(O)O)CP(=O)(O)O)CP(=O)(O)O | ligand | Lu | null | 25 | figure 26 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DMPDTMP | CC(C)(CN(CP(=O)(O)O)CP(=O)(O)O)CN(CP(=O)(O)O)CP(=O)(O)O | ligand | Lu | null | 25 | figure 26 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DTPMP | O=P(O)(O)CN(CCN(CP(=O)(O)O)CP(=O)(O)O)CCN(CP(=O)(O)O)CP(=O)(O)O | ligand | Lu | null | 25 | figure 26 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | TTHMP | O=P(O)(O)CN(CCN(CCN(CP(=O)(O)O)CP(=O)(O)O)CP(=O)(O)O)CCN(CP(=O)(O)O)CP(=O)(O)O | ligand | Lu | null | 25 | figure 26 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | CTMP | O=P(O)(O)CN1CCCN(CP(=O)(O)O)CCN(CP(=O)(O)O)CCCN(CP(=O)(O)O)CC1 | ligand | Lu | null | 25 | figure 26 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | DOTMP | O=P(O)(O)CN1CCN(CP(=O)(O)O)CCN(CP(=O)(O)O)CCN(CP(=O)(O)O)CC1 | ligand | Lu | null | 25 | figure 26 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | Estradiol−DOTA | CC12CCC3c4ccc(O)cc4C(NC(=S)Nc4ccc(CC5CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CCN5CC(=O)O)cc4)CC3C1CCC2O | ligand | Lu | null | 27 | figure 28 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | Porphyrin−DOTA | O=C(O)COc1ccc(C2=C3C=CC(=N3)C(c3ccc(OCC(=O)O)cc3)=c3ccc([nH]3)=C(c3ccc(OCC(=O)O)cc3)C3C=CC(=C(c4ccc(OCC(=O)Nc5ccc(CC6CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CCN6CC(=O)O)cc5)cc4)c4ccc2[nH]4)N3)cc1 | ligand | Lu | null | 27 | figure 29 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | Metronidazole-p-aminobenzyl DOTA | Cc1ncc([N+](=O)[O-])n1CCOC(=O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1 | ligand | Lu | null | 28 | figure 30 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | derivative-p-amino-DOTA-anilide | O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)Nc2ccc(NC(=O)CCNC(=O)Cn3cncn3)cc2)CCN(CC(=O)O)CC1 | ligand | Lu | null | 28 | figure 31 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | BPAMD | O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)NC(P(=O)(O)O)P(=O)(O)O)CCN(CC(=O)O)CC1 | ligand | Lu | null | 33 | figure 36 | 1 | title | null | null |
banerjee2015 | 10.1021/cr500171e | 10.1021/cr500171e | 0 | Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications | American Chemical Society (ACS) | 2,015 | 0 | null | texaphyrin | CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO | environment | Lu | null | 35 | figure 39 | 1 | title | null | null |
sarbisheh2019 | 10.1007/978-3-319-98947-1_20 | 10.1007/978-3-319-98947-1_20 | 0 | The Radiopharmaceutical Chemistry of the Radioisotopes of Lutetium and Yttrium | Springer International Publishing | 2,019 | 0 | 3a | p-SCN-Bn-5p-C-NETA | O=C(O)CN1CCN(CC(=O)O)CCN(CC(CCCCCc2ccc(N=C=S)cc2)N(CC(=O)O)CC(=O)O)CC1 | ligand | Lu | null | 6 | figure 3 | 3 | subtitle | null | null |
sarbisheh2019 | 10.1007/978-3-319-98947-1_20 | 10.1007/978-3-319-98947-1_20 | 0 | The Radiopharmaceutical Chemistry of the Radioisotopes of Lutetium and Yttrium | Springer International Publishing | 2,019 | 0 | 3b | p-SCN-Bn-DOTA | O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)C(Cc2ccc(N=C=S)cc2)CN(CC(=O)O)CC1 | ligand | Lu | null | 6 | figure 3 | 3 | subtitle | null | null |
sarbisheh2019 | 10.1007/978-3-319-98947-1_20 | 10.1007/978-3-319-98947-1_20 | 0 | The Radiopharmaceutical Chemistry of the Radioisotopes of Lutetium and Yttrium | Springer International Publishing | 2,019 | 0 | 3c | p-SCN-Bn-H4octapa | O=C(O)CN(Cc1cccc(C(=O)O)n1)CC(Cc1ccc(N=C=S)cc1)N(CC(=O)O)Cc1cccc(C(=O)O)n1 | ligand | Lu | null | 6 | figure 3 | 3 | subtitle | null | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.